The IPO of the Science and Technology Innovation Board of Shurui Co., Ltd. has inquired about approval for the listing of the first single-hole surgical robot in China

The Zhitong Finance App learned that on July 15, Beijing Shurui Robotics Co., Ltd. (Shurui Co., Ltd.) applied for listing on the Shanghai Stock Exchange Science and Technology Innovation Board and changed its review status to “Inquired”. CITIC Securities is the sponsor and plans to raise 700 million yuan.

According to the prospectus, Shurui Co., Ltd. is a high-tech medical device enterprise dedicated to independently developing, producing and commercializing minimally invasive endoscopic surgery robot systems and supporting equipment products with international technological leadership, with original underlying technology as the core. The products can be applied to multiple interdisciplinary treatments such as urology, gynecology, general surgery, thoracic surgery, etc., and plans to expand to departments such as head and neck surgery and cardiac surgery to provide patients with less traumatic, more accurate, and safer minimally invasive surgical solutions.

The company's first core product, the thoracic and abdominal endoscopic single-hole surgery system (SR-ENS-600), was approved for marketing by the State Drug Administration in June 2023, and is now approved for use in urology, gynecology, general surgery, thoracic pulmonary endoscopic surgery; it obtained EU CE certification in August 2025, approved for use in urology, gynecology, general surgery, and thoracic endoscopic surgery. It can be used to treat benign or malignant diseases in the chest or abdominal cavity, and is suitable for adult and pediatric patients who meet minimally invasive surgical conditions. This product is the first single-hole surgical robot approved for marketing in China and the second in the world. It is also the first Chinese surgical robot approved for use by all people in the European Union. As of the end of the reporting period, it is the only single-hole surgical robot in the world that has obtained CE certification and can be used in pediatric surgery.

The company has set up subsidiaries in Hong Kong, China and the Netherlands, and formed a high-quality overseas business team. The team members have many years of experience in leading overseas medical equipment and device companies. As of the date of signing this prospectus, the thoracic and abdominal endoscopic single-hole surgery system (SR-ENS-600) has obtained registration certificates in regions other than mainland China, such as the European Union, Hong Kong, and Malaysia. Furthermore, the issuer officially signed long-term strategic cooperation agreements or preliminary cooperation intentions with IRCAD, a world-renowned minimally invasive surgery training institution, and several well-known European teaching hospitals to accelerate the implementation of overseas commercialization strategies led by mature Western European markets.

The company has established a comprehensive intellectual property protection system. As of December 31, 2025, the company has applied for a total of 732 patents, and 471 patents have been granted, including 319 invention patents, including 148 domestically authorized invention patents, and 171 overseas (including the United States, Europe, Canada, Japan and South Korea).

The company has not made a profit during the reporting period and has accumulated uncompensated losses. The main reason is that the company has been engaged in minimally invasive endoscopic surgery robot research and development since its establishment. The business has a long R&D cycle and large capital investment. Since the establishment of the joint stock company, the amount of the company's uncompensated losses has been drastically reduced, but the company may continue to lose money for some time to come, and the amount of accumulated uncompensated losses may continue to increase.

On the financial side, in 2023, 2024 and 2025, the company achieved operating income of approximately RMB 4.49 million, RMB 119 million and RMB 81 million respectively; for the same period, net profit was -191 million yuan, -195 million yuan and -132 million yuan, respectively.